Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Liabilities from Discontinued Operations: 2021-2025

  • Ligand Pharmaceuticals' Liabilities from Discontinued Operations was N/A to $35.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $35.7 million, marking a year-over-year change of. This contributed to the annual value of $55.5 million for FY2021, which is N/A change from last year.
  • According to the latest figures from Q2 2025, Ligand Pharmaceuticals' Liabilities from Discontinued Operations is $35.7 million, which was up 39.92% from $25.5 million recorded in Q1 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Liabilities from Discontinued Operations peaked at $55.5 million during Q4 2021, and registered a low of $25.5 million during Q1 2025.
  • For the 1-year period, Ligand Pharmaceuticals' Liabilities from Discontinued Operations averaged around $30.6 million, with its median value being $30.6 million (2025).